TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04340193
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT04340193
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT01515007
Drug: Ciprofloxacin dispersion for inhalation
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06091579
Drug: Treprostinil Palmitil Inhalation Powder
Normalized name: treprostinil Inhalation Powder
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral inhalation using a Plastiape capsule-based dry powder inhaler.
Study: NCT03768505
Drug: Zandelisib (ME-401)
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib (ME-401) 60 mg
Study: NCT04330183
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3mg/kg of ketamine
Study: NCT02815566
Drug: tenofovir-alafenamide-emtricitabine
Normalized name: emtricitabine / tenofovir alafenamide
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
Study: NCT02815566
Drug: tenofovir-emtricitabine
Normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
Study: NCT01557270
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
Study: NCT01557270
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine + saline placebo, single shot perineural application
Study: NCT06010056
Drug: Ketamine-Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
Study: NCT06010056
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA morphine (Pfizer Inc., US) 1 mg ml-1
Study: NCT04147533
Drug: Imatinib withdrawal
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
Study: NCT04147533
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
Study: NCT04147533
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
Study: NCT02324985
Drug: Vehicle Topical Gel
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Topical Gel applied every 6 hours
Study: NCT04576793
Drug: 11C-ER176
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Study: NCT04576793
Drug: 18F-MK6240
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
Study: NCT00562627
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative and 1. postoperative day
Study: NCT00562627
Drug: adrenaline
Normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative LIA (IV and IA) and continuous EDA
Study: NCT00562627
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative
Study: NCT00562627
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous postoperatively
Study: NCT01764425
Drug: P7435
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
Study: NCT00597701
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
Study: NCT00597701
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms.
Study: NCT04576793
Drug: 18F-Florbetaben
Normalized name: florbetaben (18F)
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
Study: NCT00122278
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 10mg IV
Study: NCT01155219
Drug: Xalatan
Normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one drop in the conjunctival sac of each eye in the morning (84 days).
Study: NCT00892918
Drug: Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
Study: NCT00170885
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05073640
Drug: Oxopurin
Normalized name: 6-Thioxopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive two capsules per day.
Study: NCT00460369
Drug: sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake
Study: NCT00460369
Drug: amodiaquine-artesunate coformulation
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg
Study: NCT02252887
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02252887
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02252887
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03438318
Drug: CMP-001
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.
Study: NCT03438318
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
Study: NCT01816971
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT00446342
Drug: SNS-032 Injection
Normalized name: sn-3-GPC
DrugBank: SNS-032 (DB05969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1
Study: NCT01816971
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02889692
Drug: Erlotinib®
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops.
Study: NCT01816971
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02889692
Drug: Gefitinib®
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops.
Study: NCT02889692
Drug: Icotinib®
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops.
Study: NCT04398251
Drug: Febuxostat 40mg Tab
Normalized name: FEBUXOSTAT 40MG TAB
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
Study: NCT00877201
Drug: CDR2
Normalized name: (y49t)bv5s2 cdr2 peptide
DrugBank: IR-901 (DB17932)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00364754
Drug: Tesmilifene (YMB 1002)
Normalized name: Tesmilifene
DrugBank: Tesmilifene (DB04905)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01904539
Drug: obeticholic acid 10 mg
Normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose OCA 10mg in each arm
Study: NCT02231164
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous chemotherapy drug
Study: NCT00351000
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04439279
Drug: Trametinib Dimethyl Sulfoxide
Normalized name: Trametinib Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02231164
Drug: nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral experimental therapy
Study: NCT02315599
Drug: anti-CD19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03504397
Drug: zolbetuximab
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
Study: NCT03504397
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
Study: NCT03504397
Drug: folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Study: NCT04180215
Drug: HB-201 intravenous administration + standard of care regimen including pembrolizumab.
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Expansion
Study: NCT04180215
Drug: HB-202 / HB-201 alternating intravenous administration + pembrolizumab.
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Expansion
Study: NCT03982862
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone 4mg diluted to 0.1 ml
Study: NCT04180215
Drug: HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Expansion
Study: NCT00743782
Drug: Synthetic Human Parathyroid Hormone 1-34
Normalized name: Parathyroid hormone (1-84) human recombinant
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04602689
Drug: Human fibrinogen concentrate
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
Study: NCT00841971
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg IV loading dose followed by 100 mg qd for 21 days
Study: NCT00841971
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg IV for 21 days
Study: NCT03566511
Drug: Diazoxide
Normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
Study: NCT01087242
Drug: Tang-min Lin pill
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tang-min Lin pill 6g,tid,treat 12 weeks.
Study: NCT02723994
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
Study: NCT02723994
Drug: Asparaginase Erwinia Chrysanthemi
Normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02741271
Drug: MF MDI 100 mcg BID (Open Label)
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
Study: NCT02723994
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02723994
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02723994
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723994
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723994
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02741271
Drug: MF MDI 100 mcg BID
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
Study: NCT02741271
Drug: Albuterol/Salbutamol PRN
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
Study: NCT02741271
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
Study: NCT01151787
Drug: cyclobenzaprine hydrochloride
Normalized name: Cyclobenzaprine Hydrochloride
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg daily for 3 months
Study: NCT02723994
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03793556
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole, 2 capsules 20 mg, once a day before breakfast
Study: NCT02570165
Drug: Batefenterol
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
Study: NCT02570165
Drug: Umeclidinium/ Vilanterol
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
Study: NCT03774979
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Study: NCT00668031
Drug: Trasylol (Aprotinin, BAYA0128)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
Study: NCT03982862
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1ml 2% Xylocaine
Study: NCT02449681
Drug: TH-4000 (Tarloxotinib)
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03703050
Drug: Nivolumab cohort 1
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
Study: NCT03703050
Drug: Nivolumab cohort 2
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
Study: NCT00001181
Drug: Testolactone
Normalized name: Testolactone
DrugBank: Testolactone (DB00894)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04060862
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
Study: NCT04060862
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
Study: NCT04060862
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
Study: NCT03251495
Drug: Vaxchora
Normalized name: Vaxchora
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.